Patents Assigned to FRED
  • Publication number: 20200237827
    Abstract: The use of luteinizing hormone receptor (LHR) binding agents and luteinizing hormone (LH) agonists to enrich for primitive hematopoietic stem cell (pHSC) populations, to target pHSC for ablation, and/or to expand pHSC populations are described. The methods can be used to prepare therapeutic hematopoietic stem cell (HSC) populations, to prepare patients for therapeutic HSC transplants, and/or to treat malignancies, such as those associated with hyperproliferative HSC.
    Type: Application
    Filed: October 2, 2018
    Publication date: July 30, 2020
    Applicants: Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center
    Inventors: Jarrod Dudakov, Marcel van den Brink, Enrico Velardi, Hans-Peter Kiem, Stefan Radtke, Scott James
  • Patent number: 10726101
    Abstract: Various embodiments of the present disclosure comprise methods, apparatus, systems and software for use in implementing acceptance and commitment therapy (ACT). The methods include notifying or reminding users to track completion of exercises, and to track and/or monitor awareness of urges and the number of times the user allows urges to pass. Also, physical sensors can be employed to help monitor the user's detrimental behaviors and to send notifications or reminders to the user to perform exercises or track urges.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: July 28, 2020
    Assignee: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventor: Jonathan Bricker
  • Patent number: 10702551
    Abstract: The present disclosure provides compositions and methods for the delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse. The compositions comprise (i) a structure comprising an injectable polymer or scaffold comprising pores; (ii) lymphocytes disposed within the structure, (iii) at least one lymphocyte-adhesion moiety associated with the structure; and (iv) at least one lymphocyte-activating moiety associated with the structure, and optionally an immune stimulant.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: July 7, 2020
    Assignee: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventor: Matthias Stephan
  • Publication number: 20200199534
    Abstract: Therapeutic formulations containing CD34+ stem cells derived from negative selection are described. The cells within the formulations can be genetically-modified for a number of therapeutic purposes. The disclosure is particularly useful for the treatment of patients with fragile stem cells or stem cells with low CD34+ expression levels.
    Type: Application
    Filed: April 27, 2018
    Publication date: June 25, 2020
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Jennifer E. Adair, Hans-Peter Kiem
  • Patent number: 10690651
    Abstract: The invention disclosed herein generally relates to methods and kits for diagnosing, assessing disease risk, treating, and preventing bacterial vaginosis (BV) and associated conditions. Additional embodiments include methods for developing metabolic profiles associated with increased disease risk, and developing new approaches to treat BV based on interrupting metabolic networks.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: June 23, 2020
    Assignee: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Sujatha Srinivasan, David N. Fredricks
  • Publication number: 20200190220
    Abstract: Circular handed alpha-helical repeat proteins are described. The repeat proteins have a number of uses as scaffolds for geometrically precise, arrayed presentation of cell-signaling or immune-related protein and peptide epitopes, as well as numerous other therapeutic, diagnostic, and nanotechnological uses.
    Type: Application
    Filed: February 26, 2020
    Publication date: June 18, 2020
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Philip Bradley, Barry L. Stoddard
  • Patent number: 10676746
    Abstract: The present invention provides methods for treating cancers having a mutation in one or more tumor suppressor genes, comprising providing to a subject in need thereof an inhibitor of a kinase, as well as related methods and compositions.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: June 9, 2020
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Christopher Kemp, Carla Grandori, Eduardo Mendez, Russell Moser, Chang Xu
  • Publication number: 20200164059
    Abstract: Anti-Epstein Barr Virus (EBV) antibodies and vaccines are described herein. The antibodies and vaccines can be used to treat and/or reduce the risk of EBV infection and to treat and/or reduce the risk of complications associated with EBV infection, such as infectious mononucleosis, lymphoproliferative disorders, carcinomas, and smooth muscle tumors.
    Type: Application
    Filed: May 10, 2018
    Publication date: May 28, 2020
    Applicant: Fred Hutchinson Cancer Research Center
    Inventor: Andrew McGuire
  • Publication number: 20200164060
    Abstract: Herpes Simplex Virus type 2 (HSV-2) epitopes bound by CD8 or CD4 tissue resident memory cells at a healed site of HSV-2 infection are disclosed. The HSV-2 epitopes can be used as immunogenic compositions to elicit protective immune responses against HSV-2.
    Type: Application
    Filed: July 20, 2018
    Publication date: May 28, 2020
    Applicants: Fred Hutchinson Cancer Research Center, University of Washington
    Inventors: David Koelle, Anna Wald, Christine Johnston, Christine Posavad, Larry Corey
  • Patent number: 10653756
    Abstract: This invention provides, among other things, methods for the identification and isolation of viable putative long-lived antigen-specific memory CD8+ T cell subsets (CMhi and EMhi) with high surface expression of CD161 and/or IL-18R? and the capacity to rapidly efflux the fluorescent dye Rh123.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: May 19, 2020
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Cameron J. Turtle, Stanley R. Riddell
  • Publication number: 20200148767
    Abstract: Anti-CD33 antibodies are described. The anti-CD33 antibodies can bind within the V-set Ig-like domain or the C2-set Ig-like domain of CD33. Epitopes on the C2-set Ig-like domain can provide a “pan-binding” site, to which the cognate antibody will bind regardless of whether the CD33 molecule also contains the V-set domain (as in, for example, CD33FL) or not (as in, for example, CD33?E2). Alternative epitopes on the C2-set Ig-like domain are accessible for binding if the V-set domain is absent (e.g., as in CD33?E2). Antibodies that bind an epitope on the C2-set Ig-like domain (whether they exhibit pan or V-set absent binding) are directed at novel therapeutic targets and can increase therapeutic efficacy against CD33-related disorders. Also described are molecules comprising a binding-competent domain from at least one described anti-CD33 antibody, including scFvs, bi-specific antibody molecules, chimeric antigen receptors, and immunoconjugates. Methods of use are also provided.
    Type: Application
    Filed: May 25, 2018
    Publication date: May 14, 2020
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Roland B. Walter, Christopher Mehlin, George S. Laszlo, Colin E. Correnti
  • Patent number: 10639321
    Abstract: The present disclosure provides compositions, kits, and methods to protect organs by inducing acquired cytoresistance without causing injury to the organ. The compositions, kits, and methods utilize heme proteins, iron and/or vitamin B12 and, optionally, agents that impact heme protein metabolism.
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: May 5, 2020
    Assignee: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Richard Zager, Ali C M Johnson
  • Publication number: 20200123219
    Abstract: Systems and methods to increase the efficacy of vaccines that require or are rendered more effective with T cell mediated immunity are described. The systems and methods utilize polynucleotides that genetically modify T cells to express a T cell receptor specific for an administered vaccine antigen.
    Type: Application
    Filed: January 5, 2018
    Publication date: April 23, 2020
    Applicant: Fred Hutchinson Cancer Research Center
    Inventor: Matthias STEPHAN
  • Publication number: 20200115459
    Abstract: The present invention relates to methods of treating immune disorders, particularly autoimmune and inflammatory disorders such as rheumatoid arthritis, and methods of producing antibodies for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies that specifically bind to NKG2D receptors present on the surface of cells underlying the disorders.
    Type: Application
    Filed: December 11, 2019
    Publication date: April 16, 2020
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Thomas Spies, Veronika Spies
  • Patent number: 10619140
    Abstract: Provided are compositions and methods for the treatment of hemoglobinopathies such as thalassemias and sickle cell disease. Compositions and methods include one or more endonuclease(s) or endonuclease fusion protein(s), including one or more homing endonuclease(s) and/or homing endonuclease fusion protein(s) and/or CRISPR endonuclease(s) and/or CRISPR endonuclease fusion protein(s): (a) to disrupt a Bcl11a coding region; (b) to disrupt a Bcl11a gene regulatory region; (c) to modify an adult human ?-globin locus; (d) to disrupt a HbF silencing DNA regulatory element or pathway, such as a Bcl11a-regulated HbF silencing region; (e) to mutate one or more ?-globin gene promoter(s) to achieve increased expression of a ?-globin gene; (f) to mutate one or more ?-globin gene promoter(s) to achieve increased expression of a ?-globin gene; and/or (g) to correct one or more ?-globin gene mutation(s).
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: April 14, 2020
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Ryo Takeuchi, Mark T Groudine, Barry L. Stoddard, Michael A Bender
  • Patent number: 10604805
    Abstract: The present disclosure provides a panel of nucleic acid molecule primers specific for HLA-specific alleles and other genetic polymorphisms, which are useful for quantitatively amplifying these markers to detect, diagnose, and monitor individuals who have or are at risk of certain disease conditions, such as autoimmune disease, proliferative disease, infectious disease, allograft rejection, or pregnancy-related pathologies.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: March 31, 2020
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: J. Lee Nelson, Nathalie C. Lambert, Vijayakrishna K. Gadi, Zhen Yan
  • Patent number: 10597466
    Abstract: Circular handed alpha-helical repeat proteins are described. The repeat proteins have a number of uses as scaffolds for geometrically precise, arrayed presentation of cell-signaling or immune-related protein and peptide epitopes, as well as numerous other therapeutic, diagnostic, and nanotechnological uses.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: March 24, 2020
    Assignee: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Philip Bradley, Barry L. Stoddard
  • Patent number: 10588787
    Abstract: A method and an incontinence monitoring system for estimating a volume or a volume range of a bodily output in a combination absorbent article and wetness sensor. The system comprises a combination of an absorbent article and a wetness sensor, and a processor adapted to receive an input representative of an electrical variable of the wetness sensor indicative of the occurrence of a bodily output in the absorbent article and to process the input including: characterising the input to generate a vector that is representative of the bodily output, applying one or more functions to the vector to generate one or more possible volumes of the bodily output, generating a distribution of the possible volumes, and determining a volume or a volume range for the bodily output based on the distribution of the possible volumes.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: March 17, 2020
    Assignee: Fred Bergman Healthcare Pty Ltd.
    Inventors: Hadi Mashin-Chi, Mehdi Azimi, Anushiya Arunachalam Kannan
  • Patent number: 10568778
    Abstract: The present invention relates to systems, methods and devices for determining one or more pre-existing characteristics, pre-existing states or both of a combination absorbent article and electrical circuit after connecting an electronic device to the combination absorbent article and electrical circuit. The method and system is particularly, although not exclusively, suitable for determining pre-existing characteristics such as absorbent article size, type, capacity and a pre-existing state such as whether or not the electrical circuit of the combination absorbent article and electrical circuit has been previously connected to the electronic device or another like electronic device.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: February 25, 2020
    Assignee: Fred Bergman Healthcare Pty Ltd.
    Inventors: Hadi Mashin-Chi, Peter Hubertus Aigner, Peter Curran, Mehdi Azimi, Mohammed Asef Ali
  • Publication number: 20200056224
    Abstract: Transposase-based barcoding of DNA for improved efficiency, high-accuracy sequencing is described. Transposases including transposable barcodes can be used to fragment and barcode target DNA in a single step.
    Type: Application
    Filed: April 18, 2018
    Publication date: February 20, 2020
    Applicant: Fred Hutchinson Cancer Research Center
    Inventor: Jason Bielas